GlassScriptPhysician profile
Bertha S Jalilie
NPI 1376641522
$2,519.37
in general payments reported to CMS, 2019-2025
26 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,832 · 2020: $497 · 2021: $191.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $400.72 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $271.76 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $250.85 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $204.61 | 2019-2021 | |
| Mylan Specialty L.P. | $160.70 | 2019-2020 | |
| Glaxosmithkline, LLC. | $114.26 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $105.44 | 2019 | |
| Sunovion Pharmaceuticals INC. | $91.92 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $88.87 | 2019 | |
| Novo Nordisk INC | $84.42 | 2020-2021 | |
| Lilly USA, LLC | $84.37 | 2019-2020 | |
| Amgen INC. | $83.12 | 2019-2020 | |
| Abbvie INC. | $80.90 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $79.20 | 2019-2021 | |
| Allergan, INC. | $74.37 | 2019-2020 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arbor Pharmaceuticals, INC. | $67.24 | 2019-2020 | |
| Sanofi Pasteur INC. | $44.41 | 2019-2020 | |
| Astellas Pharma US INC | $42.40 | 2020 | |
| Philips North America LLC | $40.00 | 2019 | |
| Janssen Pharmaceuticals, INC | $38.22 | 2019 | |
| Sanofi-Aventis U.S. LLC | $23.17 | 2019 | |
| Amarin Pharma, INC. | $20.67 | 2019 | |
| Seqirus USA INC | $18.57 | 2020 | |
| Bausch Health US, LLC | $18.22 | 2019 | |
| Genentech USA, INC. | $16.18 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.78 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bertha Jalilie listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.